Oragenics Inc. (OGEN): Price and Financial Metrics

Oragenics Inc. (OGEN): $1.44

0.01 (-0.69%)

POWR Rating

Component Grades








Add OGEN to Watchlist
Sign Up

Industry: Biotech




#311 of 363

in industry

OGEN Price/Volume Stats

Current price $1.44 52-week high $7.74
Prev. close $1.45 52-week low $1.00
Day low $1.40 Volume 43,800
Day high $1.57 Avg. volume 99,872
50-day MA $1.59 Dividend yield N/A
200-day MA $2.97 Market Cap 6.45M

OGEN Stock Price Chart Interactive Chart >

Oragenics Inc. (OGEN) Company Bio

Oragenics, Inc. is a biotechnology research and development company seeking to commercialize technologies based on different strains of bacterias. The Company's technologies include a replacement therapy for tooth cavity protection and a new broad-spectrum antibiotic.

OGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

OGEN Latest Social Stream

Loading social stream, please wait...

View Full OGEN Social Stream

Latest OGEN News From Around the Web

Below are the latest news stories about ORAGENICS INC that investors may wish to consider to help them evaluate OGEN as an investment opportunity.

Oragenics Issues Update to Shareholders

TAMPA, Fla., November 02, 2023--Oragenics, Inc. (NYSE American: OGEN):

Yahoo | November 2, 2023

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

TAMPA, Fla., October 18, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023.

Yahoo | October 18, 2023

Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate

TAMPA, Fla. & LAS VEGAS, October 05, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Odyssey Health, Inc. (OTCQB: ODYY) ("Odyssey") announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as

Yahoo | October 5, 2023

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

TAMPA, Fla., September 29, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This milestone follows rigorous testing and validation of Oragenics’ biological samples, which are poised to potentially revolutionize dental caries prevention by replacing harmful bacterial strains with non-pathogenic counterparts.

Yahoo | September 29, 2023

Oragenics, Inc. Announces Private Placement

TAMPA, Fla., August 07, 2023--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the "Private Placement Offering"), an aggregate of (i) 404,728 shares of the Company’s common stock, $0.001 par value (the "Common Stock"), and (ii) 404,728 shares of S

Yahoo | August 7, 2023

Read More 'OGEN' Stories Here

OGEN Price Returns

1-mo -42.63%
3-mo -2.04%
6-mo -72.73%
1-year -53.42%
3-year -96.48%
5-year -95.05%
YTD -74.41%
2023 -10.78%
2022 -76.43%
2021 -0.67%
2020 -14.15%
2019 -39.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!